These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

309 related articles for article (PubMed ID: 23807360)

  • 81. Rotavirus vaccine RIX4414 efficacy sustained during the third year of life: a randomized clinical trial in an Asian population.
    Phua KB; Lim FS; Lau YL; Nelson EA; Huang LM; Quak SH; Lee BW; van Doorn LJ; Teoh YL; Tang H; Suryakiran PV; Smolenov IV; Bock HL; Han HH
    Vaccine; 2012 Jun; 30(30):4552-7. PubMed ID: 22497874
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Safety, immunogenicity and efficacy in healthy infants of G1 and G2 human reassortant rotavirus vaccine in a new stabilizer/buffer liquid formulation.
    Clark HF; Burke CJ; Volkin DB; Offit P; Ward RL; Bresee JS; Dennehy P; Gooch WM; Malacaman E; Matson D; Walter E; Watson B; Krah DL; Dallas MJ; Schödel F; Kaplan kM; Heaton P
    Pediatr Infect Dis J; 2003 Oct; 22(10):914-20. PubMed ID: 14551493
    [TBL] [Abstract][Full Text] [Related]  

  • 83. A randomized Phase I/II study to evaluate safety and reactogenicity of a heat-stable rotavirus vaccine in healthy adults followed by evaluation of the safety, reactogenicity, and immunogenicity in infants.
    Kanchan V; Zaman K; Aziz AB; Zaman SF; Zaman F; Haque W; Khanam M; Karim MM; Kale S; Ali SK; Goveia MG; Kaplan SS; Gill D; Khan WA; Yunus M; Singh A; Clemens JD
    Hum Vaccin Immunother; 2020 Mar; 16(3):693-702. PubMed ID: 31526218
    [No Abstract]   [Full Text] [Related]  

  • 84. Immunogenicity of different dosing schedules of the human live attenuate rotavirus vaccine (RV1) in infants and children: a meta-analysis.
    Dai X; Bai R; Jian M; Ji Z; Ding Z; Wang F; Bi Y; Manzamaesso A; Chen T; Luo L; Liu A; Bao F
    Hum Vaccin Immunother; 2019; 15(6):1228-1236. PubMed ID: 30346870
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Comparative evaluation of safety and immunogenicity of two dosages of an oral live attenuated human rotavirus vaccine.
    Dennehy PH; Brady RC; Halperin SA; Ward RL; Alvey JC; Fischer FH; Innis BL; Rathfon H; Schuind A; De Vos B;
    Pediatr Infect Dis J; 2005 Jun; 24(6):481-8. PubMed ID: 15933555
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Safety and immunogenicity of RV3-BB human neonatal rotavirus vaccine administered at birth or in infancy: a randomised, double-blind, placebo-controlled trial.
    Bines JE; Danchin M; Jackson P; Handley A; Watts E; Lee KJ; West A; Cowley D; Chen MY; Barnes GL; Justice F; Buttery JP; Carlin JB; Bishop RF; Taylor B; Kirkwood CD;
    Lancet Infect Dis; 2015 Dec; 15(12):1389-97. PubMed ID: 26318715
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Rotavirus epidemiology 5-6 years after universal rotavirus vaccination: persistent rotavirus activity in older children and elderly.
    Markkula J; Hemming-Harlo M; Salminen MT; Savolainen-Kopra C; Pirhonen J; Al-Hello H; Vesikari T
    Infect Dis (Lond); 2017 May; 49(5):388-395. PubMed ID: 28067093
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Impact of withholding breastfeeding at the time of vaccination on the immunogenicity of oral rotavirus vaccine--a randomized trial.
    Ali A; Kazi AM; Cortese MM; Fleming JA; Moon S; Parashar UD; Jiang B; McNeal MM; Steele D; Bhutta Z; Zaidi AK
    PLoS One; 2015; 10(6):e0127622. PubMed ID: 26035743
    [TBL] [Abstract][Full Text] [Related]  

  • 89. European Society for Paediatric Infectious Diseases consensus recommendations for rotavirus vaccination in Europe: update 2014.
    Vesikari T; Van Damme P; Giaquinto C; Dagan R; Guarino A; Szajewska H; Usonis V
    Pediatr Infect Dis J; 2015 Jun; 34(6):635-43. PubMed ID: 25860532
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Efficacy and safety of pentavalent human-bovine reassortant rotavirus vaccine when administered with greater than 10 weeks between doses.
    Goveia MG; Suprun L; Itzler RF; McFetridge R; Dallas MJ; Kuter BJ
    Pediatr Infect Dis J; 2010 Mar; 29(3):263-5. PubMed ID: 19949360
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Vaccination of Thai infants with rhesus-human reassortant tetravalent oral rotavirus vaccine.
    Simasathien S; Migasena S; Samakoses R; Pitisuttitham P; Sangaroon P; Aree C; Bishop R; Bugg H; Davidson BL; Vesikari T
    Pediatr Infect Dis J; 1994 Jul; 13(7):590-6. PubMed ID: 7970945
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Human Neonatal Rotavirus Vaccine (RV3-BB) to Target Rotavirus from Birth.
    Bines JE; At Thobari J; Satria CD; Handley A; Watts E; Cowley D; Nirwati H; Ackland J; Standish J; Justice F; Byars G; Lee KJ; Barnes GL; Bachtiar NS; Viska Icanervilia A; Boniface K; Bogdanovic-Sakran N; Pavlic D; Bishop RF; Kirkwood CD; Buttery JP; Soenarto Y
    N Engl J Med; 2018 Feb; 378(8):719-730. PubMed ID: 29466164
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Safety and immunogenicity of tetravalent rhesus-based rotavirus vaccine in Bangladesh.
    Bresee JS; El Arifeen S; Azim T; Chakraborty J; Mounts AW; Podder G; Gentsch JR; Ward RL; Black R; Glass RI; Yunus M
    Pediatr Infect Dis J; 2001 Dec; 20(12):1136-43. PubMed ID: 11740320
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Safety, efficacy, and immunogenicity of a live, quadrivalent human-bovine reassortant rotavirus vaccine in healthy infants.
    Clark HF; Bernstein DI; Dennehy PH; Offit P; Pichichero M; Treanor J; Ward RL; Krah DL; Shaw A; Dallas MJ; Laura D; Eiden JJ; Ivanoff N; Kaplan KM; Heaton P
    J Pediatr; 2004 Feb; 144(2):184-90. PubMed ID: 14760258
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Efficacy of the pentavalent rotavirus vaccine, RotaTeq® (RV5), between doses of a 3-dose series and with less than 3 doses (incomplete regimen).
    Dennehy PH; Vesikari T; Matson DO; Itzler RF; Dallas MJ; Goveia MG; DiNubile MJ; Heaton PM; Ciarlet M
    Hum Vaccin; 2011 May; 7(5):563-8. PubMed ID: 21441783
    [TBL] [Abstract][Full Text] [Related]  

  • 96. A short report on highlights of worldwide development of RIX4414: a Singaporean experience.
    Phua KB; Quak SH; Emmanuel S; Goh PS; Han HH; Hardt K; Bock HL; De Vos B
    Vaccine; 2006 May; 24(18):3782-3. PubMed ID: 16600443
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis.
    Ruiz-Palacios GM; Pérez-Schael I; Velázquez FR; Abate H; Breuer T; Clemens SC; Cheuvart B; Espinoza F; Gillard P; Innis BL; Cervantes Y; Linhares AC; López P; Macías-Parra M; Ortega-Barría E; Richardson V; Rivera-Medina DM; Rivera L; Salinas B; Pavía-Ruz N; Salmerón J; Rüttimann R; Tinoco JC; Rubio P; Nuñez E; Guerrero ML; Yarzábal JP; Damaso S; Tornieporth N; Sáez-Llorens X; Vergara RF; Vesikari T; Bouckenooghe A; Clemens R; De Vos B; O'Ryan M;
    N Engl J Med; 2006 Jan; 354(1):11-22. PubMed ID: 16394298
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Pentavalent rotavirus vaccine (RotaTeq): a review of its use in the prevention of rotavirus gastroenteritis in Europe.
    Plosker GL
    Drugs; 2010 Jun; 70(9):1165-88. PubMed ID: 20518582
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Neonatal administration of rhesus rotavirus tetravalent vaccine.
    Vesikari T; Karvonen A; Forrest BD; Hoshino Y; Chanock RM; Kapikian AZ
    Pediatr Infect Dis J; 2006 Feb; 25(2):118-22. PubMed ID: 16462287
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Horizontal transmission of a human rotavirus vaccine strain--a randomized, placebo-controlled study in twins.
    Rivera L; Peña LM; Stainier I; Gillard P; Cheuvart B; Smolenov I; Ortega-Barria E; Han HH
    Vaccine; 2011 Nov; 29(51):9508-13. PubMed ID: 22008819
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.